Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Derm CasesDermatology / Haematology / Hepatology

Derm Cases · Dermatology / Haematology / Hepatology

OSCE — Meltzer triad and cold-precipitating immunoglobulins: manage cryoglobulinaemic disease

An 8-minute OSCE station on Brouet typing of cryoglobulins, recognising mixed cryoglobulinaemic vasculitis (purpura–arthralgia–weakness, low C4, HCV link), Type I hyperviscosity red flags, correct sample handling, and rituximab/antiviral/plasma-exchange decisions.

8 minosce2 min readVerification in progress

Target exams

NEET-PGINICETUSMLEPLABMRCP
On this page
Study tools

Target exams

NEET-PGINICETUSMLEPLABMRCP
Prompt
An 8-minute OSCE station on Brouet typing of cryoglobulins, recognising mixed cryoglobulinaemic vasculitis (purpura–arthralgia–weakness, low C4, HCV link), Type I hyperviscosity red flags, correct sample handling, and rituximab/antiviral/plasma-exchange decisions.

Brief (to candidate)

A 58-year-old with chronic hepatitis C develops recurrent lower-limb palpable purpura, arthralgia and fatigue. Complements show very low C4 with near-normal C3. RF is positive. A second card describes a patient with Waldenström macroglobulinaemia, headache and blurred vision in the cold. You have 8 minutes to classify cryoglobulinaemia, plan correct laboratory handling, and escalate therapy for vasculitis vs hyperviscosity.

[7]

Candidate instructions

  1. Explain the Brouet Type I / II / III classification.
  2. Recognise Meltzer's triad and the low C4 pattern in mixed disease.
  3. Link HCV (and other causes) and list required screens.
  4. Describe pre-analytical sample handling for cryoglobulin assay.
  5. Outline therapy: antiviral, rituximab, steroids, plasma exchange by severity/type.
[6]

Examiner checklist (mark each domain / 10)

DomainKey actions expected
DefinitionImmunoglobulins that precipitate in the cold and redissolve on rewarming; clinical disease from hyperviscosity/precipitation (Type I) or immune-complex vasculitis (mixed)[1]
Brouet typesI: monoclonal Ig (MGUS/myeloma/WM) — hyperviscosity/thrombosis more than classic vasculitis. II: monoclonal IgM RF + polyclonal IgG (mixed). III: polyclonal mixed. Mixed disease → small-vessel vasculitis[1][2]
Mixed clinicalMeltzer triad: palpable purpura, arthralgia, weakness; often very low C4, RF+, HCV association; may involve nerves and kidneys
Lab handlingBlood drawn and transported warm (37°C) to lab; improper cooling causes false negatives — state this explicitly
Cause screenHCV (and HBV/HIV as indicated), autoimmune disease, lymphoproliferative disease/SPEP-immunofixation for Type I
TherapyTreat underlying cause (DAA for HCV when appropriate); rituximab cornerstone for mixed cryoglobulinaemic vasculitis; steroids for flares; plasma exchange for severe organ-threatening disease, hyperviscosity, or critical ischaemia; haematology for Type I clone-directed therapy[5][6]
SafetyCold avoidance counselling; urgent PE pathway for hyperviscosity/RPGN/severe neuropathy

Model key actions

  • Classify Type I vs mixed and recognise purpura–arthralgia–weakness + low C4 as mixed cryoglobulinaemia.[1]
  • Always warm-handle cryoglobulin samples; screen HCV and paraprotein.[2]
  • Use rituximab ± PE for severe mixed vasculitis; treat the clone or virus driving production.[6]

Common errors

  • Sending cryoglobulin sample on ice/room-temp incorrectly.
  • Missing HCV testing in mixed disease.
  • Treating Type I hyperviscosity as simple rash without haematology/PE.
  • Ignoring renal/neurologic involvement.
  • Using prolonged steroids alone without addressing B-cell/virus drivers.
[6]
References5ShowHide
  1. [1]Roccatello D, Saadoun D, Ramos-Casals M, et al. Cryoglobulinaemia. Nature Reviews Disease Primers, 2018.PMID 30072738
  2. [2]Retamozo S, Quartuccio L, Ramos-Casals M, et al. Cryoglobulinemia. Medicina Clinica, 2022.PMID 35216803
  3. [5]Desbois AC, Cacoub P, Saadoun D. Cryoglobulinemia: An update in 2019. Joint Bone Spine, 2019.PMID 30731128
  4. [6]Quartuccio L, Bortoluzzi A, Scirè CA, et al. Management of mixed cryoglobulinemia with rituximab: evidence and consensus-based recommendations from the Italian Study Group of Cryoglobulinemia (GISC). Clinical Rheumatology, 2023.PMID 36169798
  5. [7]Saadoun D, Thibault V, Si Ahmed SN, et al. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study Ann Rheum Dis, 2016.PMID 26567178
PreviousOSCE — melanocytic pathology: biopsy, naevus vs melanoma criteria, report elementsDermatology / Dermatopathology / Skin cancer MDTNextOSCE — moles and special naevi: classification, dermoscopy patterns and biopsy thresholdsDermatology / Pigmented lesions